Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume

BACKGROUND: After neoadjuvant chemotherapy of breast cancer pathologic complete response (pCR) indicates a favorable prognosis. Among non-selected patients, pCR is, however, achieved in only 10–30%. Early evaluation of tumour response to treatment would facilitate individualized therapy, with ineffe...

Descripción completa

Detalles Bibliográficos
Autor principal: Tribukait, Bernhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236455/
https://www.ncbi.nlm.nih.gov/pubmed/32423477
http://dx.doi.org/10.1186/s12885-020-06925-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236455/
https://www.ncbi.nlm.nih.gov/pubmed/32423477
http://dx.doi.org/10.1186/s12885-020-06925-y

Ejemplares similares